Influence of bromine substitution pattern on the singlet oxygen generation efficiency of two-photon absorbing chromophores

2012 ◽  
Vol 10 (31) ◽  
pp. 6275 ◽  
Author(s):  
Pierre-Henri Lanoë ◽  
Thibault Gallavardin ◽  
Aurore Dupin ◽  
Olivier Maury ◽  
Patrice L. Baldeck ◽  
...  
2018 ◽  
Vol 153 ◽  
pp. 26-34 ◽  
Author(s):  
Semiha Yıldırım Sarıkaya ◽  
Serkan Yeşilot ◽  
Adem Kılıç ◽  
Elif Okutan

2020 ◽  
Vol 11 (9) ◽  
pp. 2494-2503 ◽  
Author(s):  
Zheng Zheng ◽  
Haixiang Liu ◽  
Shaodong Zhai ◽  
Haoke Zhang ◽  
Guogang Shan ◽  
...  

Mitochondria-targeted photosensitizers with highly efficient singlet oxygen generation, bright near-infrared AIE and good two-photon absorption are obtained through ingenious molecular engineering for cancer cell-selective photodynamic therapy.


2019 ◽  
Vol 55 (10) ◽  
pp. 1450-1453 ◽  
Author(s):  
Chengkai Zhang ◽  
Yanqian Zhao ◽  
Dandan Li ◽  
Jiejie Liu ◽  
Heguo Han ◽  
...  

Two-photon active photosensitizers showed relatively strong intersystem crossing facilitating 1O2 generation and cell apoptosis with near-infrared excitation.


2020 ◽  
Vol 24 (05n07) ◽  
pp. 603-635 ◽  
Author(s):  
Jun Wang ◽  
Qingbao Gong ◽  
Long Wang ◽  
Erhong Hao ◽  
Lijuan Jiao

Photodynamic therapy (PDT) is a minimally invasive technique for the treatment of target malignant tumors via the generation of highly reactive singlet oxygen species. PDT treatment of cancer/tumor tissues greatly relies on the development of suitable stable, highly specific and efficient photosensitizers. BODIPY (Boron dipyrromethene) derivatives, as a class of well-developed, versatile fluorescent dyes, has emerged as a new class of PDT agents over the past decade. Many elegant strategies have been developed to enhance the singlet oxygen generation efficiency and the cancer/tumor cell selectivity of BODIPY-based photosensitizers to improve the therapeutic outcomes as well as to minimize the side effects. Many of the currently reported BODIPY-based photosensitizers are valuable dual imaging and therapeutic agents, which can efficiently generate singlet oxygen for PDT and emit fluorescence for in vivo imaging. Although the currently approved PDT agents used for clinical trials do not feature BODIPYs, this situation is expected to change. In this review, we provide an overview of the various strategies that have been used to improve the singlet oxygen generation efficiency for tuning BODIPY fluorophores into photosensitizers and dual imaging/therapeutic agents. Their photophysical properties and photocytotoxic activity including the absorption/emission wavelengths, the singlet oxygen generation efficiency ([Formula: see text] and the half maximal inhibitory concentration [Formula: see text] of these currently reported photosensitizers are summarized. We believe these newly developed BODIPY-based photosensitizers will broaden current concepts of strategies for PDT agent design, and promise to make an important contribution to the diagnosis and therapeutics for the treatment of cancer.


Tetrahedron ◽  
2015 ◽  
Vol 71 (7) ◽  
pp. 1088-1094 ◽  
Author(s):  
Sébastien Picard ◽  
Guillaume Clermont ◽  
Emilie Genin ◽  
Mireille Blanchard-Desce

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Qiang Zhao ◽  
Yao Wang ◽  
Yanshuang Xu ◽  
Yun Yan ◽  
Jianbin Huang

Sign in / Sign up

Export Citation Format

Share Document